Alterity Therapeutics Limited (F:PBN) — Market Cap & Net Worth
Market Cap & Net Worth: Alterity Therapeutics Limited (PBN)
Alterity Therapeutics Limited (F:PBN) has a market capitalization of $65.25 Million (€55.81 Million) as of August 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #20811 globally and #1879 in its home market, demonstrating a -4.85% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alterity Therapeutics Limited's stock price €0.31 by its total outstanding shares 10875416329 (10.88 Billion). Review PBN total debt and obligations to assess the company's total debt and financial obligations.
Alterity Therapeutics Limited Market Cap History: 2015 to 2026
Alterity Therapeutics Limited's market capitalization history from 2015 to 2026. Data shows growth from $762.87 Million to $3.99 Billion (15.39% CAGR).
Alterity Therapeutics Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alterity Therapeutics Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
-1221.84x
Alterity Therapeutics Limited's market cap is -1221.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $254.29 Million | $142.66K | -$7.73 Million | 1782.53x | N/A |
| 2017 | $432.29 Million | $132.40K | -$7.54 Million | 3265.15x | N/A |
| 2018 | $139.86 Million | $201.17K | -$8.27 Million | 695.22x | N/A |
| 2019 | $114.43 Million | $108.54K | -$12.34 Million | 1054.29x | N/A |
| 2021 | $127.15 Million | $-7.58K | -$15.31 Million | -16773.75x | N/A |
| 2022 | $6.36 Million | $-5.20K | -$12.85 Million | -1221.84x | N/A |
Competitor Companies of PBN by Market Capitalization
Companies near Alterity Therapeutics Limited in the global market cap rankings as of August 5, 2026.
Key companies related to Alterity Therapeutics Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
Alterity Therapeutics Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Alterity Therapeutics Limited's market cap moved from $762.87 Million to $ 3.99 Billion, with a yearly change of 15.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €3.99 Billion | +7750.00% |
| 2025 | €50.86 Million | +14.29% |
| 2024 | €44.50 Million | +75.00% |
| 2023 | €25.43 Million | +300.00% |
| 2022 | €6.36 Million | -95.00% |
| 2021 | €127.15 Million | -39.39% |
| 2020 | €209.79 Million | +83.33% |
| 2019 | €114.43 Million | -18.18% |
| 2018 | €139.86 Million | -67.65% |
| 2017 | €432.29 Million | +70.00% |
| 2016 | €254.29 Million | -66.67% |
| 2015 | €762.87 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Alterity Therapeutics Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $65.25 Million USD |
| MoneyControl | $65.25 Million USD |
| MarketWatch | $65.25 Million USD |
| marketcap.company | $65.25 Million USD |
| Reuters | $65.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alterity Therapeutics Limited
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more